Monique Fayad & Marla Dubinsky of Trellus Health discuss the major milestones achieved in 2021 & strategy for 2022
Episode 702, May 10, 2022, 01:39 PM
Monique Fayad, CEO & Marla Dubinsky, Co- founder of Trellus Health #TRLS & Director, Icahn School Of Medicine Mount Sinai New York discuss the major milestones achieved in 2021 including the AIM IPO raising $40.4m, launching TrellusElevateTM platform & strategy for 2022.
Monique Fayad, CEO & Marla Dubinsky, Co- founder of Trellus Health #TRLS & Director, Icahn School Of Medicine, Mount Sinai, New York discuss the major milestones achieved in 2021 including their AIM IPO, raising $40.4m, launching TrellusElevateTM platform & their strategy for 2022.
Financial Highlights
· Successful admission to AIM with fundraising of gross proceeds of c. $40.4m (£28.5m)
· Approximately $4.3m capital investment in technology platform development to date
· Net cash of $32.0m (31 December 2020: $3.7m) - above market expectations, reflecting effective cash management
· Adjusted EBITDA* loss of $5.7m, in line with expectations (FY 2020: $0.8m loss)
* Earnings before interest, tax, depreciation and amortisation adjusted for exceptional items
Key Accomplishments
· TrellusElevateTM platform launched, along with companion App
· Established organization, operations and licensed clinical team - licensed in NY, NJ and CT and credentialed in Mount Sinai Clinical Integrated Network
· First Business-to-Business ("B2B") demonstration contract with Mount Sinai Health System
· Managed Services Organization agreement with Connected Health Medicine PC, a Professional Corporation that provides multidisciplinary patient care services via telehealth
· Evaluated condition expansion opportunities beyond IBD with targeted expansion to address IBS - 30m US patients / $61bn annual healthcare spend
Post-period end
· Launch of Direct-to-Consumer ("DTC") offering
· Evolution to a new service delivery model utilizing an integrated resilience team, to address certain regulatory challenges, costs and delays associated with establishing licensed clinical care management operations. This new delivery model will support the broader, more efficient and profitable scaling of both DTC and BTB value propositions across all 50 US states and will enable Trellus Health to move more rapidly into other chronic conditions.